<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>supplements | ALS | MND</title><link>/tag/supplements/</link><atom:link href="/tag/supplements/index.xml" rel="self" type="application/rss+xml"/><description>supplements</description><generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language><lastBuildDate>Sat, 27 Jun 2020 00:00:00 +0000</lastBuildDate><image><url>/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png</url><title>supplements</title><link>/tag/supplements/</link></image><item><title>Melatonin</title><link>/alternative-treatment/melatonin/</link><pubDate>Sat, 27 Jun 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/melatonin/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>Melatonin is a naturally occurring hormone that is best known for its role in sleep regulation. After screening more than a thousand FDA-approved drugs several years ago, researchers determined that melatonin is a powerful antioxidant that blocks the release of enzymes that activate apoptosis, or programmed cell death.&lt;/p>
&lt;h2 id="dosage">Dosage&lt;/h2>
&lt;p>&lt;span>&lt;small>&lt;em>Those have been taken out of the articles for your convenience&lt;/em>&lt;/small>&lt;/span>&lt;/p>
&lt;ul>
&lt;li>300mg/day as suppository&lt;/li>
&lt;/ul>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h3 id="2013---melatonin-slows-als-symptoms-in-micehttpswwwfuturityorgmelatonin-slows-als-symptoms-in-mice">&lt;a href="https://www.futurity.org/melatonin-slows-als-symptoms-in-mice/" target="_blank" rel="noopener">2013 - Melatonin slows als symptoms in mice&lt;/a>&lt;/h3>
&lt;h3 id="2006---reduced-oxidative-damage-in-als-by-high-dose-enteral-melatonin-treatment">2006 - Reduced oxidative damage in ALS by high-dose enteral melatonin treatment&lt;/h3>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./reduced_oxidative_damage_in_als_by_high.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>[&amp;hellip;] melatonin slowed disease progression by 25% or 73%, depending on the definition of &amp;ldquo;disease onset&amp;rdquo;, by the appearance of first tremor or failure on the rotarod, respectively.&lt;/p>
&lt;/blockquote>
&lt;blockquote>
&lt;p>Translating these findings to human ALS, we are aware that a cure by melatonin is unlikely. An increase in life expectancy, however, is a worth-while goal, specifically during the early stages of this disease.&lt;/p>
&lt;/blockquote></description></item><item><title>Carnitine</title><link>/alternative-treatment/carnitine/</link><pubDate>Sat, 09 May 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/carnitine/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>Acetyl-L-carnitine supplies L-carnitine, which is important in the transport of long chain fatty acids across mitochondrial membranes. In addition, the acetyl moiety can be transferred to provide acetyl CoA. Therefore, acetyl-L-carnitine improves cerebral oxidative energy production and fatty acid oxidation in muscles. It has shown beneficial effects in models of traumatic brain and spinal cord injury, cerebral ischemia, stroke and patients with Alzheimer&amp;rsquo;s disease. In primary motor neuron cultures from rats, acetyl-L-carnitine was found to protect against kainate and NMDA-induced toxicity. In light of this, a randomized double blind placebo-controlled trial was performed in small number of patients with ALS to investigate the effects of add-on acetyl-L-carnitine to riluzole vs. riluzole only treatment. Patients tolerated the combination well and had a better score in the ALS Functional Rating Scale&lt;sup id="fnref:1">&lt;a href="#fn:1" class="footnote-ref" role="doc-noteref">1&lt;/a>&lt;/sup>&lt;/p>
&lt;h3 id="mechanisms2">Mechanisms:&lt;sup id="fnref:2">&lt;a href="#fn:2" class="footnote-ref" role="doc-noteref">2&lt;/a>&lt;/sup>&lt;/h3>
&lt;ul>
&lt;li>Enhanced exercise performance&lt;/li>
&lt;li>Reduced oxidative stress&lt;/li>
&lt;li>Enhanced mitochondrial energy production&lt;/li>
&lt;li>Protection against excitotoxicity&lt;/li>
&lt;li>Neurotrophic effects&lt;/li>
&lt;li>Increased heat shock proteins&lt;/li>
&lt;/ul>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;h4 id="2020---als-untangled-no-53-carnitine-supplementshttpswwwtandfonlinecomdoifull1010802167842120201726565">&lt;a href="https://www.tandfonline.com/doi/full/10.1080/21678421.2020.1726565" target="_blank" rel="noopener">2020 - ALS Untangled No. 53: Carnitine Supplements&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./carnitine_supplements.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>In conclusion, there are good theoretical mechanisms for carnitines, some pre-clinical evidence for LC and ALCAR, and a single clinical trial that suggested ALCAR could slow disease progression in PALS. All three carnitines appear to be well-tolerated, generally safe and inexpensive. We believe that there is a need for future clinical trials of carnitines in PALS to further elucidate their efficacy. Until there is further data, we cannot endorse any of these supplements as a definite way to slow ALS progression; &lt;strong>however, oral ALCAR at 1000mg three times daily (3000mg total daily dose) appears to be a theoretically promising supplement available for PALS whom would like to self-experiment&lt;/strong>&lt;/p>
&lt;/blockquote>
&lt;h4 id="2013---randomised-double-blind-placebo-controlled-trial-of-acetyl-l-carnitine">2013 - Randomised double-blind placebo controlled trial of acetyl-L-carnitine&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./randomized_double_blinf_placebo_controller_trial_of_acetyl_l_carnitine_for_als.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>Trial referenced in the ALS Untangle review&lt;/p>
&lt;/blockquote>
&lt;h2 id="suggested-dose">Suggested Dose&lt;/h2>
&lt;p>Acetyl-L-Carnitine: 1000mg three times daily (3000mg total daily dose)&lt;/p>
&lt;h2 id="natural-sources">Natural Sources&lt;/h2>
&lt;p>Animal-based foods are good sources of carnitine, including:&lt;sup id="fnref:3">&lt;a href="#fn:3" class="footnote-ref" role="doc-noteref">3&lt;/a>&lt;/sup>&lt;/p>
&lt;ul>
&lt;li>Beef, 4 oz cooked - 56-162 mg&lt;/li>
&lt;li>Chicken, 4 oz cooked - 3-5 mg&lt;/li>
&lt;li>Milk, 1 cup whole - 8 mg&lt;/li>
&lt;li>Cheese, 2 oz cheddar - 2 mg&lt;/li>
&lt;li>Cheese, 2 oz cheddar - 2 mg&lt;/li>
&lt;/ul>
&lt;h2 id="supplements">Supplements&lt;/h2>
&lt;h3 id="consumerlab-acetyl-l-carnitine-product-review">Consumerlab acetyl-l-carnitine product review&lt;/h3>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./consumerlab_acetyl-l-carnitine_supplement_review.pdf">Download PDF&lt;/a>&lt;/p>
&lt;section class="footnotes" role="doc-endnotes">
&lt;hr>
&lt;ol>
&lt;li id="fn:1" role="doc-endnote">
&lt;p>excerpt from &lt;a href="https://www.frontiersin.org/articles/10.3389/fnins.2016.00611/full#B59">https://www.frontiersin.org/articles/10.3389/fnins.2016.00611/full#B59&lt;/a> &lt;a href="#fnref:1" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:2" role="doc-endnote">
&lt;p>excerpt from &lt;a href="https://www.tandfonline.com/doi/full/10.1080/21678421.2020.1726565">https://www.tandfonline.com/doi/full/10.1080/21678421.2020.1726565&lt;/a> &lt;a href="#fnref:2" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:3" role="doc-endnote">
&lt;p>excerpt from &lt;a href="https://www.webmd.com/vitamins-and-supplements/acetyl-l-carnitine-uses-risks#1-3">https://www.webmd.com/vitamins-and-supplements/acetyl-l-carnitine-uses-risks#1-3&lt;/a> &lt;a href="#fnref:3" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;/ol>
&lt;/section></description></item><item><title>MitoQ (coq10)</title><link>/alternative-treatment/coq10/</link><pubDate>Sat, 09 May 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/coq10/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>MitoQ is an antioxidant. Its active ingredient is ubiquinone, as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting cells in culture from oxidative stress&lt;/p>
&lt;p>Oxidative stress is believed to play a major role in ALS pathogenesis&lt;sup id="fnref:1">&lt;a href="#fn:1" class="footnote-ref" role="doc-noteref">1&lt;/a>&lt;/sup>. Unfortunately, trials of antioxidants have thus far failed to show any benefits in patients with ALS&lt;sup id="fnref:2">&lt;a href="#fn:2" class="footnote-ref" role="doc-noteref">2&lt;/a>&lt;/sup> &lt;sup id="fnref:3">&lt;a href="#fn:3" class="footnote-ref" role="doc-noteref">3&lt;/a>&lt;/sup>. One explanation for these failures is that the antioxidants did not reach the optimal place. Since mitochondria are both the main producer and main target of oxidative stress, mitochondrial-focused antioxidant therapy might be more successful. Orally administered MitoQ can alter markers of both oxidative stress and mitochondrial dysfunction in cell culture&lt;sup id="fnref:4">&lt;a href="#fn:4" class="footnote-ref" role="doc-noteref">4&lt;/a>&lt;/sup> and animal model of ALS (11).&lt;/p>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h4 id="2015---antioxidant-mitoq-shown-as-a-promising-therapy-for-alshttpsalsnewstodaycom20150716antioxidant-mitoq-shown-promising-therapy-als">&lt;a href="https://alsnewstoday.com/2015/07/16/antioxidant-mitoq-shown-promising-therapy-als/" target="_blank" rel="noopener">2015 - Antioxidant MitoQ Shown As A Promising Therapy for ALS&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./antioxidant_mitoq_shown_as_a_promising _therapy_for_als.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>“This study supports the role of mitochondrial dysfunction in the development and progression of ALS, which may allow
for the development of more mitochondria-targeted therapies to fight this disease,” concluded study’s co-author and
Director of the Center, Dr. Rafael Radi. “We also found that MitoQ has beneficial effects in the murine model of ALS,
which will likely lead to clinical trials using MitoQ with ALS patients and hopefully lead to extend the survival and
improve the quality of life of ALS patients.”&lt;/p>
&lt;/blockquote>
&lt;h4 id="2015---an-overview-of-potential-targets-for-treating-amyotrophic-lateral-sclerosis-and-huntingtons-diseasehttpswwwhindawicomjournalsbmri2015198612">&lt;a href="https://www.hindawi.com/journals/bmri/2015/198612/" target="_blank" rel="noopener">2015 - An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington’s Disease&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./an_overview_of_potential_targets_for_treating_amyotrophic_lateral_sclerosis_and_huntingtons_disease.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>MitoQ is a mitochondrial antioxidant that contains the antioxidant Quinone linked to a lipophilic
triphenylphosphonium cation. Researchers showed that MitoQ prolonged life span and the pathology of SOD-knockout Drosophila melanogaster,
the enzyme involved in ALS. In addition, the compound has been shown to exert neuroprotective effects in SODG93A mice, slowing functional decline,
decreasing oxidative damage and disease progression, and increasing survival.&lt;br>
Furthermore, other studies showed that MitoQ preincubation prevented the cell death observed in cultures of motor
neurons + SOD-mutant astrocytes alone.&lt;/p>
&lt;/blockquote>
&lt;h4 id="2015---als-untangled-no-29-mitoqhttpswwwtandfonlinecomdoifull1031092167842120151050897">&lt;a href="https://www.tandfonline.com/doi/full/10.3109/21678421.2015.1050897" target="_blank" rel="noopener">2015 - ALS Untangled No. 29: MitoQ&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./als_untangled_29_mitoq.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>MitoQ has a promising mechanism, positive preclinical data from two different ALS models, and appears reasonably safe
and inexpensive, especially at doses of 10 mg daily. Available anecdotal data are insufficient to determine how helpful
this might be in PALS. A small open-label pilot trial with validated ALS diagnoses and outcomes appears warranted.&lt;/p>
&lt;/blockquote>
&lt;section class="footnotes" role="doc-endnotes">
&lt;hr>
&lt;ol>
&lt;li id="fn:1" role="doc-endnote">
&lt;p>Carri M, Valle C, Bozzo F, Cozzolino M.Oxidative stress and mitochondrial damage: importance in non-SOD1 ALS . Front Cell Neurosci. 2015;9:41.
&lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0007&amp;amp;dbid=8&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=25741238" target="_blank" rel="noopener">PubMed&lt;/a>, &lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0007&amp;amp;dbid=128&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=000349604900001" target="_blank" rel="noopener">Web of Science ®&lt;/a>, &lt;a href="http://scholar.google.com/scholar_lookup?hl=en&amp;amp;publication_year=2015&amp;amp;pages=41&amp;amp;author=M&amp;#43;Carri&amp;amp;author=C&amp;#43;Valle&amp;amp;author=F&amp;#43;Bozzo&amp;amp;author=M.&amp;#43;Cozzolino&amp;amp;title=Oxidative&amp;#43;stress&amp;#43;and&amp;#43;mitochondrial&amp;#43;damage%3A&amp;#43;importance&amp;#43;in&amp;#43;non-SOD1&amp;#43;ALS" target="_blank" rel="noopener">Google Scholar&lt;/a> &lt;a href="#fnref:1" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:2" role="doc-endnote">
&lt;p>Kaufmann P, Thompson J, Buchsbaum R, Shefner J, Krivickas L, Katz J, et al.Phase II trial of coq10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:234–44.
&lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0008&amp;amp;dbid=16&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=10.1002%2Fana.21743" target="_blank" rel="noopener">Crossref&lt;/a>, &lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0008&amp;amp;dbid=128&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=000269845400017" target="_blank" rel="noopener">Web of Science ®&lt;/a>, &lt;a href="http://scholar.google.com/scholar_lookup?hl=en&amp;amp;publication_year=2009&amp;amp;pages=234-44&amp;amp;author=P&amp;#43;Kaufmann&amp;amp;author=J&amp;#43;Thompson&amp;amp;author=R&amp;#43;Buchsbaum&amp;amp;author=J&amp;#43;Shefner&amp;amp;author=L&amp;#43;Krivickas&amp;amp;author=J&amp;#43;Katz&amp;amp;title=Phase&amp;#43;II&amp;#43;trial&amp;#43;of&amp;#43;coq10&amp;#43;for&amp;#43;ALS&amp;#43;finds&amp;#43;insufficient&amp;#43;evidence&amp;#43;to&amp;#43;justify&amp;#43;phase&amp;#43;III" target="_blank" rel="noopener">Google Scholar&lt;/a> &lt;a href="#fnref:2" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:3" role="doc-endnote">
&lt;p>Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al.High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo controlled double-blind study. J Neural Transm. 2005;112:646–60.
&lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0009&amp;amp;dbid=16&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=10.1007%2Fs00702-004-0220-1" target="_blank" rel="noopener">Crossref&lt;/a>, &lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0009&amp;amp;dbid=128&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=000229439700005" target="_blank" rel="noopener">Web of Science ®&lt;/a>, &lt;a href="http://scholar.google.com/scholar_lookup?hl=en&amp;amp;publication_year=2005&amp;amp;pages=646-60&amp;amp;author=M&amp;#43;Graf&amp;amp;author=D&amp;#43;Ecker&amp;amp;author=R&amp;#43;Horowski&amp;amp;author=B&amp;#43;Kramer&amp;amp;author=P&amp;#43;Riederer&amp;amp;author=M&amp;#43;Gerlach&amp;amp;title=High&amp;#43;dose&amp;#43;vitamin&amp;#43;E&amp;#43;therapy&amp;#43;in&amp;#43;amyotrophic&amp;#43;lateral&amp;#43;sclerosis&amp;#43;as&amp;#43;add-on&amp;#43;therapy&amp;#43;to&amp;#43;riluzole%3A&amp;#43;results&amp;#43;of&amp;#43;a&amp;#43;placebo&amp;#43;controlled&amp;#43;double-blind&amp;#43;study." target="_blank" rel="noopener">Google Scholar&lt;/a> &lt;a href="#fnref:3" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:4" role="doc-endnote">
&lt;p>Cassina P, Cassina A, Pehar M, Castellanos R, Gandelman M, de Leon A, et al.Journal Neurosci. 2008;16:4115–22.
&lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0010&amp;amp;dbid=16&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=10.1523%2FJNEUROSCI.5308-07.2008" target="_blank" rel="noopener">Crossref&lt;/a>, &lt;a href="https://www.tandfonline.com/servlet/linkout?suffix=CIT0010&amp;amp;dbid=128&amp;amp;doi=10.3109%2F21678421.2015.1050897&amp;amp;key=000255012500004" target="_blank" rel="noopener">Web of Science ®&lt;/a>, &lt;a href="http://scholar.google.com/scholar?hl=en&amp;amp;q=Cassina&amp;#43;P%2C&amp;#43;Cassina&amp;#43;A%2C&amp;#43;Pehar&amp;#43;M%2C&amp;#43;Castellanos&amp;#43;R%2C&amp;#43;Gandelman&amp;#43;M%2C&amp;#43;de&amp;#43;Leon&amp;#43;A%2C&amp;#43;et&amp;#43;al.Journal&amp;#43;Neurosci.&amp;#43;2008%3B16%3A4115%E2%80%9322." target="_blank" rel="noopener">Google Scholar&lt;/a> &lt;a href="#fnref:4" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;/ol>
&lt;/section></description></item><item><title>NAD</title><link>/alternative-treatment/nad-precursors/</link><pubDate>Sat, 09 May 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/nad-precursors/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;h3 id="what-is-nad">What is NAD&lt;/h3>
&lt;p>&lt;img style="float: left;" src="./nad_cycle.jpeg">Nicotinamide adenine dinucleotide (NAD) is a cofactor central to metabolism. Found in all living cells, NAD is called a dinucleotide because it consists of two nucleotides joined through their phosphate groups. One nucleotide contains an adenine nucleobase and the other nicotinamide. NAD exists in two forms: an oxidized and reduced form, abbreviated as NAD+ and NADH respectively.&lt;sup id="fnref:1">&lt;a href="#fn:1" class="footnote-ref" role="doc-noteref">1&lt;/a>&lt;/sup>&lt;/p>
&lt;p>[&amp;hellip;]There are three major functions of NAD. First, it allows us to convert our food into ATP, which is the biological chemical currency that allows us to move our muscles, have ideas, and run all of our cells. Second, NAD also catalyzes conversion of the food we eat into everything we are, including DNA, RNA, proteins, hormones and lipids. Third, NAD helps us to repair cellular damage to DNA, protein and fat that is caused by the way we live our lives, what we eat or drink, how we sleep, travel, sun, the air we breath, stress and just plain old wear-and-tear. &lt;sup id="fnref:2">&lt;a href="#fn:2" class="footnote-ref" role="doc-noteref">2&lt;/a>&lt;/sup>&lt;/p>
&lt;h3 id="what-are-nmn-na-and-nr">What are NMN, NA and NR?&lt;/h3>
&lt;p>Nicotinamide or Niacinamide (NAM)
Nicotinamide mononucleotide (NMN)
Nicotinic Acid or Niacin (NA)&lt;br>
NR (Nicotinamide Riboside)&lt;/p>
&lt;p>are all precursors of NAD&lt;/p>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h3 id="nr">NR&lt;/h3>
&lt;blockquote>
&lt;p>Patented by ChromaDex, sold under TruNiagen. Could also be found in Elysium Health &amp;lsquo;Basis&amp;rsquo; product though manufacturer is unknown at the time of writing.&lt;/p>
&lt;/blockquote>
&lt;h4 id="evaluation-of-the-nad-biosynthetic-pathway-in-als-patients-and-effect-of-modulating-nad-levels-in-hsod1-linked-als-mouse-modelshttpswwwsciencedirectcomsciencearticlepiis0014488620300509via3dihub">&lt;a href="https://www.sciencedirect.com/science/article/pii/S0014488620300509?via%3Dihub" target="_blank" rel="noopener">Evaluation of the NAD+ biosynthetic pathway in ALS patients and effect of modulating NAD+ levels in hSOD1-linked ALS mouse models&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./evalutaion_of_the_nad+_biosynthetic_pathways_in_als_patient.pdf">Download PDF&lt;/a>&lt;/p>
&lt;h4 id="eh301---nr--pt-pterostilbene">EH301 - NR + PT (pterostilbene)&lt;/h4>
&lt;ul>
&lt;li>19 Feb 2019&lt;br>
&lt;a href="https://www.trialsitenews.com/university-of-valencia-research-reveals-that-eh301-may-halt-als-progression/" target="_blank" rel="noopener">University of Valencia Research Reveals that eH301 May Halt ALS Progression&lt;/a>&lt;/li>
&lt;li>18 Feb 2019
&lt;a href="https://www.alzforum.org/news/research-news/small-trial-eh301-appears-halt-progression-als" target="_blank" rel="noopener">In Small Trial, EH301 Appears to Halt Progression of ALS&lt;/a>&lt;/li>
&lt;li>&lt;strong>PDF - Jan 2019&lt;/strong>
&lt;a href="./eh301_study.pdf">Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study&lt;/a>&lt;/li>
&lt;li>3 Apr 2018
&lt;a href="https://alsnewstoday.com/2018/04/03/eh301-granted-orphan-drug-designation-amyotrophic-lateral-sclerosis/" target="_blank" rel="noopener">Elysium Health’s EH301 Designated Orphan Drug by FDA for Treatment of ALS&lt;/a>&lt;/li>
&lt;/ul>
&lt;h3 id="nmn">NMN&lt;/h3>
&lt;h4 id="nmn-as-a-potential-therapeutic-agent-for-muscle-diseasehttpswwwnmncomnewsnmn-as-potential-therapeutic-agent-for-muscle-disease">&lt;a href="https://www.nmn.com/news/nmn-as-potential-therapeutic-agent-for-muscle-disease" target="_blank" rel="noopener">NMN as a potential therapeutic agent for muscle disease&lt;/a>&lt;/h4>
&lt;h4 id="enhancing-nad-salvage-pathway-reverts-the-toxicity-of-primary-astrocytes-expressing-amyotrophic-lateral-sclerosis-linked-mutant-superoxide-dismutase-1-sod1httpswwwncbinlmnihgovpubmed27002158">&lt;a href="https://www.ncbi.nlm.nih.gov/pubmed/27002158" target="_blank" rel="noopener">Enhancing NAD+ Salvage Pathway Reverts the Toxicity of Primary Astrocytes Expressing Amyotrophic Lateral Sclerosis-linked Mutant Superoxide Dismutase 1 (SOD1)&lt;/a>&lt;/h4>
&lt;section class="footnotes" role="doc-endnotes">
&lt;hr>
&lt;ol>
&lt;li id="fn:1" role="doc-endnote">
&lt;p>&lt;a href="https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide">https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide&lt;/a> &lt;a href="#fnref:1" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;li id="fn:2" role="doc-endnote">
&lt;p>&lt;a href="https://www.foodmatterslive.com/news-and-comment/news/chromadex-nad">https://www.foodmatterslive.com/news-and-comment/news/chromadex-nad&lt;/a> &lt;a href="#fnref:2" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;/ol>
&lt;/section></description></item><item><title>Theracurmin</title><link>/alternative-treatment/theracurmin/</link><pubDate>Sat, 09 May 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/theracurmin/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;p>Curcumin has been shown to produce neuroprotective effects. It’s a compound in turmeric (a member of the ginger family), which is often used in the diet and medicines of Southeast Asia, China, and India.&lt;/p>
&lt;p>Curcumin is able to cross the blood brain barrier (BBB) — a highly selective membrane that shields the central nervous system from general blood circulation — which makes it an ideal therapeutic candidate for diseases of the central nervous system (brain and spinal cord), such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease.&lt;/p>
&lt;p>Theracurmin (nanocurmin) is a more bio aaialable version of normal curcumin supplements.&lt;/p>
&lt;h3 id="mechanisms1">Mechanisms:&lt;sup id="fnref:1">&lt;a href="#fn:1" class="footnote-ref" role="doc-noteref">1&lt;/a>&lt;/sup>&lt;/h3>
&lt;ul>
&lt;li>decrease neuroinflammation&lt;/li>
&lt;li>prevent oxidative stress&lt;/li>
&lt;li>might inhibit protein aggregation&lt;/li>
&lt;li>alter fecal microbiome&lt;/li>
&lt;/ul>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h4 id="2018---als-untangled-44---curcuminhttpswwwtandfonlinecomdoifull1010802167842120181440738">&lt;a href="https://www.tandfonline.com/doi/full/10.1080/21678421.2018.1440738" target="_blank" rel="noopener">2018 - ALS Untangled 44 - Curcumin&lt;/a>&lt;/h4>
&lt;p>&lt;a class="btn btn-outline-primary" target="_blank" rel="noopener noreferrer" href="./als_untangled_44_curcumin.pdf">Download PDF&lt;/a>&lt;/p>
&lt;blockquote>
&lt;p>Oral curcumin is safe, inexpensive, and has at least four potential mechanisms by which it might theoretically be useful in treating PALS. Flawed preclinical studies showed benefits of a curcumin chemical analog in a cell model of ALS, three PALS experienced validated motor improvements on regimens including curcumin (although there are several alternative explanations for these improvements) and there is one small pilot trial showing some benefit of curcumin in PALS. Based on the evidence presented in this review, some of us are planning a trial of Theracurmin at 90 mg twice daily in PALS.&lt;/p>
&lt;/blockquote>
&lt;h2 id="supplements">Supplements&lt;/h2>
&lt;ul>
&lt;li>&lt;strong>Theracurmin&lt;/strong>&lt;br>
&lt;a href="https://www.amazon.com/gp/product/B0765DHTVL/ref=as_li_tl?ie=UTF8&amp;amp;tag=alsmnd-20&amp;amp;camp=1789&amp;amp;creative=9325&amp;amp;linkCode=as2&amp;amp;creativeASIN=B0765DHTVL&amp;amp;linkId=1fd73afdf55d78d45d58d0ac32178413" target="_blank" rel="noopener">Buy on Amazon&lt;/a>&lt;br>
Dosage: 90mg with breakfast, 90mg with diner&lt;/li>
&lt;/ul>
&lt;section class="footnotes" role="doc-endnotes">
&lt;hr>
&lt;ol>
&lt;li id="fn:1" role="doc-endnote">
&lt;p>excerpt from &lt;a href="https://www.tandfonline.com/doi/full/10.1080/21678421.2018.1440738">https://www.tandfonline.com/doi/full/10.1080/21678421.2018.1440738&lt;/a> &lt;a href="#fnref:1" class="footnote-backref" role="doc-backlink">&amp;#x21a9;&amp;#xfe0e;&lt;/a>&lt;/p>
&lt;/li>
&lt;/ol>
&lt;/section></description></item><item><title>Vitamin B-12</title><link>/alternative-treatment/vitamin-b12/</link><pubDate>Sat, 09 May 2020 00:00:00 +0000</pubDate><guid>/alternative-treatment/vitamin-b12/</guid><description>&lt;h2 id="science">Science&lt;/h2>
&lt;h2 id="articles">Articles&lt;/h2>
&lt;div class="alert alert-note">
&lt;div>
The titles of the articles are clickable and will redirect you to the online resource.
The quote is the conclusion or an extract of the article.
Please be sure to read them fully
&lt;/div>
&lt;/div>
&lt;h3 id="high-dose-vitamin-b12-may-improve-als-prognosis-if-started-early-study-suggestshttpsalsnewstodaycom20190117high-dose-vitamin-b12-helpful-early-diagnosis">&lt;a href="https://alsnewstoday.com/2019/01/17/high-dose-vitamin-b12-helpful-early-diagnosis/" target="_blank" rel="noopener">High-dose Vitamin B12 May Improve ALS Prognosis if Started Early, Study Suggests&lt;/a>&lt;/h3>
&lt;blockquote>
&lt;p>In conclusion, ultra-high-dose methylcobalamin was not found to be significantly superior to placebo. However, ultra-high-dose methylcobalamin therapy may improve the prognosis of patients with ALS, if administered early in the disease course,&lt;/p>
&lt;/blockquote>
&lt;h3 id="ultra-high-dose-methylcobalamin-in-amyotrophic-lateral-sclerosis-a-long-term-phase-iiiii-randomised-controlled-study">Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study&lt;/h3></description></item></channel></rss>